Colorectal cancer (CRC) is predominantly an adult malignancy, rarely affecting children, with an incidence of less than 1% in individuals under 20 years old. Pediatric CRC typically presents with nonspecific symptoms, leading to delayed diagnosis and poorer outcomes compared to adults. Cutaneous metastases in CRC are exceedingly rare, occurring in 0.7%-5% of cases, and have not been previously reported in pediatric patients. We present an 11-year-old male with rectal adenocarcinoma who developed cutaneous metastasis after initial treatment. Misdiagnosis and delayed presentation contributed to disease progression. Treatment included neoadjuvant chemoradiotherapy, surgical resection, and adjuvant chemotherapy. Despite initial symptom resolution, the patient experienced tumor recurrence with peritoneal carcinomatosis and subsequent cutaneous metastasis, ultimately succumbing to the disease. This case highlights the challenges of diagnosing and managing pediatric CRC, emphasizing the need for heightened clinical suspicion and improved access to diagnostic tools, especially in resource-limited settings.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881688 | PMC |
http://dx.doi.org/10.1093/jscr/rjaf096 | DOI Listing |
Discov Oncol
March 2025
Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality. Using the Galaxy platform, the present study aimed to assess the differentially expressed genes (DEGs) in CRC patients. The expression data was obtained from the Gene Expression Omnibus database (GSE137327).
View Article and Find Full Text PDFCancer Rep (Hoboken)
March 2025
Department of General Surgery, The People's Hospital of Wuhai Inner Mongolia, Wuhai, Inner Mongolia, China.
Background: Colorectal cancer (CRC) stands as the second most prevalent cause of cancer-related mortality globally, while its incidence holds the third position among newly diagnosed cancer cases worldwide. Colorectal carcinogenesis is complicated, and the processes are triggered by the complex interaction of some genetic and environmental factors, including DNA methylation. Previous studies showed that RALYL is hypermethylated in CRC.
View Article and Find Full Text PDFJ Surg Case Rep
March 2025
University of Kharoum, Khartoum, Sudan.
Colorectal cancer (CRC) is predominantly an adult malignancy, rarely affecting children, with an incidence of less than 1% in individuals under 20 years old. Pediatric CRC typically presents with nonspecific symptoms, leading to delayed diagnosis and poorer outcomes compared to adults. Cutaneous metastases in CRC are exceedingly rare, occurring in 0.
View Article and Find Full Text PDFCancer Nurs
March 2025
Author Affiliations: College of Public Health (Drs Brown and Medcalf), Departments of Neurological Sciences (Dr Poppert Corts) and Pediatrics (Dr Acquazzino); and College of Nursing (Dr Lally), University of Nebraska Medical Center, Omaha.
Background: People with late-stage and metastatic colorectal cancer (CRC) are living longer, with rates increasing over time, necessitating a greater understanding of their survivorship experiences.
Objective: The purpose of this study was to explore the quality of life (QoL) and cancer-related experiences of stages III and IV CRC survivors and to inform oncology nursing practice and survivorship care.
Interventions/methods: This sequential, explanatory mixed-method study used a cross-sectional Functional Assessment of Cancer Therapy-Colorectal survey and semistructured interviews to explore QoL and cancer-related experiences of stages III and IV CRC survivors.
Exp Hematol Oncol
March 2025
Department of Pediatrics, Affiliated Hospital of Guizhou Medical University, No. 28 Guiyi Street, Yunyan District, Guiyang, 550000, Guizhou, China.
Background: Acute myeloid leukemia (AML) is a prevalent malignancy of the hematologic system. Despite advancements in therapeutic approaches, significant heterogeneity and therapeutic resistance pose substantial challenges to treatment. Tumors driven by core transcription factors through super-enhancers can establish core transcriptional regulatory circuits (CRCs) that modulate oncogene expression programs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!